Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease
Muriel Noetzli, Chin B. Eap
Clinical Pharmacokinetics (2013) Vol. 52, Iss. 4, pp. 225-241
Closed Access | Times Cited: 192

Showing 1-25 of 192 citing articles:

Alzheimer's disease
Colin L. Masters, Randall J. Bateman, Kaj Blennow, et al.
Nature Reviews Disease Primers (2015) Vol. 1, Iss. 1
Closed Access | Times Cited: 1435
Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs
Mukta Agrawal, Swarnlata Saraf, Shailendra Saraf, et al.
Journal of Controlled Release (2018) Vol. 281, pp. 139-177
Closed Access | Times Cited: 500
Rodent models for Alzheimer disease
Jürgen Götz, Liviu‐Gabriel Bodea, Michel Goedert
Nature reviews. Neuroscience (2018) Vol. 19, Iss. 10, pp. 583-598
Closed Access | Times Cited: 304
Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice
Yi Liu, Yuyun Zhang, Xian Zheng, et al.
Journal of Neuroinflammation (2018) Vol. 15, Iss. 1
Open Access | Times Cited: 217
Prescribing in Older People
David G. Le Couteur, Sarah N. Hilmer, Nicholas Glasgow, et al.
(2025), pp. 627-712
Closed Access | Times Cited: 62
Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs
Samridhi Thakral, Alka Yadav, Vikramjeet Singh, et al.
Ageing Research Reviews (2023) Vol. 88, pp. 101960-101960
Closed Access | Times Cited: 52
Alzheimer’s disease and its treatment–yesterday, today, and tomorrow
A. Y. Kim, Salman Al Jerdi, Ryan B. MacDonald, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 22
Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer’s Disease: Present Status and Future Opportunities
Muhammad Ovais, Nashmia Zia, Irshad Ahmad, et al.
Frontiers in Aging Neuroscience (2018) Vol. 10
Open Access | Times Cited: 122
The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease
William James Deardorff, Eliahu S. Feen, George T. Grossberg
Drugs & Aging (2015) Vol. 32, Iss. 7, pp. 537-547
Closed Access | Times Cited: 118
Physiologically-based pharmacokinetic models: approaches for enabling personalized medicine
Clara Hartmanshenn, Megerle L. Scherholz, Ioannis P. Androulakis
Journal of Pharmacokinetics and Pharmacodynamics (2016) Vol. 43, Iss. 5, pp. 481-504
Open Access | Times Cited: 99
Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer’s Disease: Are Irreversible Inhibitors the Future?
Donald E. Moss
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 10, pp. 3438-3438
Open Access | Times Cited: 84
Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease
Anton Meden, Damijan Knez, Marko Jukič, et al.
Chemical Communications (2019) Vol. 55, Iss. 26, pp. 3765-3768
Closed Access | Times Cited: 80
Adverse Drug Reactions of Acetylcholinesterase Inhibitors in Older People Living with Dementia: A Comprehensive Literature Review
Sirasa Ruangritchankul, Prawat Chantharit, Sahaphume Srisuma, et al.
Therapeutics and Clinical Risk Management (2021) Vol. Volume 17, pp. 927-949
Open Access | Times Cited: 70
Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
Ashvin Varadharajan, Aarjith Damian Davis, Aishwarya Ghosh, et al.
Journal of Neurosciences in Rural Practice (2023) Vol. 14, pp. 566-573
Open Access | Times Cited: 33
Cognitive disorders in patients with chronic kidney disease: Approaches to prevention and treatment
Marion Pépin, Aleksandra Klimkowicz‐Mrowiec, Olivier Godefroy, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 9, pp. 2899-2911
Open Access | Times Cited: 27
The impact of genetic variability on Alzheimer’s therapies: obstacles for pharmacogenetic progress
Ramón Cacabelos, Olaia Martínez-Iglesias, Natalia Cacabelos, et al.
Expert Opinion on Drug Metabolism & Toxicology (2025), pp. 1-28
Closed Access | Times Cited: 1
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities
Damijan Knez, Nicolas Coquelle, Anja Pišlar, et al.
European Journal of Medicinal Chemistry (2018) Vol. 156, pp. 598-617
Closed Access | Times Cited: 83
The benefit of docosahexaenoic acid for the adult brain in aging and dementia
Norman Salem, Milène Vandal, Frédéric Calon
Prostaglandins Leukotrienes and Essential Fatty Acids (2014) Vol. 92, pp. 15-22
Open Access | Times Cited: 82
Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
Robert Wyse, Gary Dunbar, Julien Rossignol
International Journal of Molecular Sciences (2014) Vol. 15, Iss. 2, pp. 1719-1745
Open Access | Times Cited: 78
Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development
Ramón Cacabelos, Pablo Cacabelos, Clara Torrellas, et al.
Methods in molecular biology (2014), pp. 323-556
Closed Access | Times Cited: 74
Pharmacokinetic and pharmacodynamic alterations in older people with dementia
Emily Reeve, Shanna Trenaman, Kenneth Rockwood, et al.
Expert Opinion on Drug Metabolism & Toxicology (2017) Vol. 13, Iss. 6, pp. 651-668
Closed Access | Times Cited: 65
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation
Dana Mohammad, Parco Chan, Janelle Bradley, et al.
Expert Opinion on Drug Safety (2017) Vol. 16, Iss. 9, pp. 1009-1019
Closed Access | Times Cited: 63
Neurotherapeutic applications of nanomedicine for treating Alzheimer's disease
Barnabas Wilson, K. Geetha
Journal of Controlled Release (2020) Vol. 325, pp. 25-37
Closed Access | Times Cited: 51
Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders
Маргарита Е. Неганова, Yulia Aleksandrova, Olga Sukocheva, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 805-833
Closed Access | Times Cited: 29
Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?
Laura Marinela Ailioaie, Constantin Ailioaie, Gerhard Litscher
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 916-916
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top